Alʹmanah Kliničeskoj Mediciny, 2023 The priority treatment approach for prolactinomas is therapy with dopamine agonists, which allows for elimination of clinical symptoms, normalization of prolactin levels, reduction of the adenoma size and prevention of metabolic abnormalities in the ...
Irena A. Ilovayskaya, Gulnar R. Vagapova
doaj +1 more source
Dopamine agonists and antipsychotics [PDF]
European Journal of Endocrinology, 2020 There can potentially be a number of clinical interactions that could adversely affect patient outcomes in a patient with a prolactinoma and psychiatric disease that might require antipsychotic and dopamine agonist treatment. Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size
openaire +2 more sources
Adsorption properties of dopamine derivatives using carbon nanotubes: A first-principles study [PDF]
Applied Surface Science, Volume 501, 31 January 2020, 144249, 2020 Detecting dopamine is of great biological importance because the molecule plays many roles in the human body. For instance, the lack of dopamine release is the cause of Parkinson's disease. Although many researchers have carried out experiments on dopamine detection using carbon nanotubes (CNTs), there are only a few theoretical studies on this topic ...
arxiv +1 more source
Cholinergic modulation of dopamine overflow in the rat neostriatum: A fast cyclic voltammetric study in vitro [PDF]
, 1994 Stimulus-evoked dopamine overflow in rat neostriatal slices was determined using fast cyclic voltammetry. The dopamine efflux induced by intrastriatal stimulation increased with stimulus intensity and was found to be enhanced by more than 100% upon ...
Kudernatsch, Martina, Sutor, Bernd
core +1 more source
Predictors of dopamine agonist resistance in prolactinoma patients
BMC Endocrine Disorders, 2020 Background Surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to identify a subgroup of patients who may benefit from early surgery, we
Elle Vermeulen +6 more
doaj +1 more source
Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations [PDF]
, 2014 In the recent years, the serotonin system has emerged as a key player in the induction of l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease. In fact, serotonin neurons possess the enzymatic machinery able to convert exogenous l-DOPA
CARTA, MANOLO, TRONCI, ELISABETTA
core +1 more source
Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment [PDF]
, 1997 Neuropsychiatric side effects often complicate anti-Parkinsonian therapy and pose a significant problem in the optimal management of idiopathic Parkinson's disease.
Abbott, R.J. +6 more
core +2 more sources
Dopamine Agonists: From the 1970s to Today
Neuroendocrinology, 2019 The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting ...
R. Auriemma +4 more
semanticscholar +1 more source
Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. [PDF]
, 2013 RationaleImpaired cognitive abilities are a key characteristic of schizophrenia. Although currently approved pharmacological treatments have demonstrated efficacy for positive symptoms, to date no pharmacological treatments successfully reverse cognitive
Acheson, Dean T +2 more
core +2 more sources
RGS4 regulates partial agonism of the M2 muscarinic receptor-activated K+ currents. [PDF]
, 2014 Partial agonists are used clinically to avoid overstimulation of receptor-mediated signalling, as they produce a submaximal response even at 100% receptor occupancy.
Chen, I-Shan +3 more
core +2 more sources